Who
Jennifer Zachary
EVP, General Counsel
Company insider
Files Form 4 as: EVP, General Counsel, Merck & Company; Director, Regenxbio.
In numbers
- Trades disclosed
- 91
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $83.1M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 May 2018
- Last trade
- 12 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $4.9M41,494 at $117.89 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $1.1M13,433 at $84.71 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $10.7M80,315 at $133.46 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —41,494 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,433 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —41,494 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,433 at $0.00 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $4.9M41,494 at $117.89 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $1.1M13,433 at $84.71 | filing |
| 12 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $10.7M80,315 at $133.46 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,064 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,312 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,064 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,312 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $325K2,951 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $160K1,454 at $110.03 | filing |
News
Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsMRK · biopharmadive.com · 22 Oct 2026Merck & Co., Inc. $MRK Stock Sold by Smith Chas P & Associates PA CpasMRK · dailypolitical.com · 22 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026
0 headlines in the last 90 days name Jennifer Zachary; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.